Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

The collab aims to educate small-to-medium-sized clinics on how to effectively deliver novel psychedelic treatments, if FDA-approved. ・Osmind has tie-ups with over 1,000 clinics in the U.S. that offer ...

Quest Diagnostics Incorporated , a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, ...

Osmind, the platform powering the largest network of independent psychiatry practices, and CareNet GPO, a group purchasing organization focused on psychiatry and behavioral health, today announced an ...

Operator: Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Q4 2025 Results Conference Call. [Operator Instructions] This call is being recorded on Tuesday, March 24, 2026. I ...

NRx Pharmaceuticals announced it received confirmatory minutes from an FDA Type C meeting outlining a path to New Drug Approval for NRX-100 (ketamine) to treat depression, including patients with ...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system (CNS) disorders, ...

NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) ...

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, ...

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.